Current Strategy of Chemotherapy for Bone Tumors.
10.4055/jkoa.2015.50.6.438
- Author:
Hyo Song KIM
1
;
Sun Young RHA
Author Information
1. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac
- Publication Type:Review
- Keywords:
bone tumor;
chemotherapy
- MeSH:
Adolescent;
Child;
Drug Therapy*;
Giant Cell Tumors;
Humans;
Osteosarcoma;
Population Characteristics;
Recurrence;
Sarcoma, Ewing;
Survival Rate;
Denosumab
- From:The Journal of the Korean Orthopaedic Association
2015;50(6):438-443
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Despite the rarity of primary bone tumors, osteosarcoma and Ewing sarcoma are the most common primary malignant bone tumors in children and adolescents. Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment remarkably improved the survival outcome for patients with osteosarcoma and Ewing sarcoma, therefore, most patients are now limb-salvage candidates. However, survival rate reached a plateau for last decades and is still unsatisfactory in the metastatic and relapse setting. Therefore, as seen in denosumab in giant cell tumor, further clinical trials based on molecular mechanism are warranted. This article reviews the current state of the art of systemic chemotherapy by focusing on the clinical heterogeneity of each subtype.
